QUOTE AND NEWS
newratings.com  Apr 29  Comment 
WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) partner Viking Therapeutics Inc. (VKTX) announced that it has priced its initial public offering of 3 million shares of its common stock at an initial offering price to the public of $8.00...
FierceBiotech  Apr 22  Comment 
Ronald Evans, the heavyweight Salk Institute researcher and serial entrepreneur who co-founded Ligand Pharmaceuticals, Syndax, and X-Ceptor, is putting his shoulder behind a new stealth biotech in San Diego named Metacrine.
Benzinga  Apr 20  Comment 
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the first presentation of preclinical data demonstrating single agent and combination activity of two of TG Therapeutics' IRAK4...
Motley Fool  Mar 15  Comment 
It's expensive -- but this biotech stock still looks like a bargain.
Benzinga  Mar 3  Comment 
CRT Capital initiated coverage on Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) with a Buy rating. The target price for Ligand Pharmaceuticals is set to $102. Ligand Pharmaceuticals shares have dropped 13.54% over the past 52 weeks, while...
TheStreet.com  Feb 11  Comment 
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.  TheStreet Ratings quantitative algorithm...
Benzinga  Feb 9  Comment 
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) reported in-line earnings for the fourth quarter. The La Jolla, California-based company posted a quarterly profit of $7.1 million, or $0.34 per share, versus $1.9 million, or $0.09 per share, in the...





You may also be interested in articles related to Ligand Pharmaceuticals (LGND):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki